APA Blogs
22 Results
Bright Light Therapy: Growing Evidence Beyond Seasonal Depression
Bright light therapy has long been a key treatment for seasonal depression. Now, new research adds to the evidence of its effectiveness for other types of depression. A study published in JAMA Psychiatry in late 2024, found that bright light therapy was an effective supplementary treatment for depressive disorders other than seasonal depression.
What Are the Latest Scientific Trends in Psychiatry and How Will They Impact Care?
Scientific advancements and technology are giving psychiatrists increasing abilities to deliver treatments tailored to individual needs. Some of these include advancements in the areas of genetics, biomarkers and imaging.
What is Borderline Personality Disorder?
Personality refers to peoples’ thoughts and views on how they relate to their world, and how they relate to others. All people have personality traits that make them unique, such as “shy” or “outgoing” or “humble” or “self-assured.” A personality disorder, however, is deeper and more severe and can cause problems in how a person thinks and feels, which can impact their perceptions and interactions with others. People with personality disorders may not realize that they are thinking or acting in unhealthy ways and tend to be unwilling to change.
Olympian Mindset: The Role of Sports Psychiatry
- By Brook Choulet, M.D.
The journey to becoming an Olympian is as much a mental endeavor as a physical one. Behind every gold medal and record-breaking performance lies preparation, mental clarity, resilience, physical training, and sacrifices. Athletes face internal and external pressures from family and coaches to their self-criticism and strides toward perfection. These factors can ultimately lead to detrimental effects on performance. However, through optimizing their mental health and overall well-being, athletes can harness the strength of their minds, leading to mental clarity, focus, and record-breaking performances.
An App for Therapy? Exploring Digital Therapeutics
In May 2024, the Food and Drug Administration approved the first app for the treatment of depression, Rejoyn. This new smartphone app is intended to help treat people who don’t fully respond to antidepressants and it is expected to be available for patients starting this summer. This is the latest in a series of FDA approvals of digital therapeutics for mental health conditions